Age-related reference values for urinary organic acids in a healthy Turkish pediatric population

Güneral, Feza; Bachmann, C.

doi:10.1093/clinchem/40.6.862

Cited by 71 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This particular metabolic situation seems to be reflected in the reduced urinary excretion of certain organic acids (including butyric and isobutyric acid) compared to older individuals where glycogen stores are fully restored [31]. Furthermore, indoleacetic acid measured in our neonatal cohort were also found to be 10-fold lower than what has been reported in the literature for neonates [32]. Both HPHPA and indoleacetic acid are known gut microbial metabolites, with HPHPA excretion being associated with gut microbial degradation of dietary phenylalanine or polyphenols [33] and indoleacetic acid being a microbially derived breakdown product of tryptophan [33].…”

Section: Comparison Of Experimental Values With Reported Reference Vacontrasting

confidence: 48%

The Urinary Metabolome of Healthy Newborns

et al. 2020

View full text Add to dashboard Cite

The knowledge of normal metabolite values for neonates is key to establishing robust cut-off values to diagnose diseases, to predict the occurrence of new diseases, to monitor a neonate's metabolism, or to assess their general health status. For full term-newborns, many reference biochemical values are available for blood, serum, plasma and cerebrospinal fluid. However, there is a surprising lack of information about normal urine concentration values for a large number of important metabolites in neonates. In the present work, we used targeted tandem mass spectrometry (MS/MS)-based metabolomic assays to identify and quantify 136 metabolites of biomedical interest in the urine from 48 healthy, full-term term neonates, collected in the first 24 h of life. In addition to this experimental study, we performed a literature review (covering the past eight years and over 500 papers) to update the references values in the Human Metabolome Database/Urine Metabolome Database (HMDB/UMDB). Notably, 86 of the experimentally measured urinary metabolites are being reported in neonates/infants for the first time and another 20 metabolites are being reported in human urine for the first time ever. Sex differences were found for 15 metabolites. The literature review allowed us to identify another 78 urinary metabolites with concentration data. As a result, reference concentration values and ranges for 378 neonatal urinary metabolites are now publicly accessible via the HMDB.

show abstract

Section: Comparison Of Experimental Values With Reported Reference Vacontrasting

confidence: 48%

The Urinary Metabolome of Healthy Newborns

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Lack of statistical significance can be attributed to high variability in the citrate concentrations in each group. It has been reported that citrate can be highly variable in human urine as a result of various individual metabolic processes 31. Other endogenous compounds like steroids can also be expected to be different in male and female urine samples as sex differences in steroid metabolism have been clearly demonstrated in clinical studies 32.…”

Section: Resultsmentioning

confidence: 99%

Development and validation of a gas chromatography/mass spectrometry metabonomic platform for the global profiling of urinary metabolites

Pasikanti

Chan

2008

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

This paper presents a simple and reliable gas chromatography/mass spectrometry (GC/MS) method for the metabonomic analysis of human urine samples. The sample preparation involved the depletion of excess urea via treatment with urease and subsequent protein precipitation using ice-cold ethanol. An aliquot of the mixture was separated, dried, trimethylsilyl (TMS)-derivatized and 1.0 microL of the derivatized extract was injected into the GC/MS system via split injection (1:10). Approximately 150 putative metabolites belonging to different chemical classes were identified from the pooled human urine samples. All the identified metabolites were selected to evaluate precision and stability of the GC/MS assay. More than 95% of the metabolites demonstrated good reproducibility, with intra-day and inter-day precision values below 15%. Metabolic profiling of 53 healthy male and female urine samples in combination with pattern recognition techniques was performed to further validate the GC/MS metabolite profiling assay. Principal component analysis (PCA) followed by orthogonal partial least squares analysis (OPLS) revealed differences between urinary metabolite profiles of healthy male and female subjects. This validated GC/MS metabolic profiling method may be further applied to the metabonomic screening of urinary biomarkers in clinical studies.

show abstract

“…Differences in urine organic acids profiles also have been reported in populations of healthy infants, with the highest median urinary MMA (95th percentile) of 5.2 (49) mmol/mol creatinine and 29.9 (78.9) mmol/mol creatinine seen at 1 and 6 months of age. 41,42 Concentrations tend to decrease with age because of the steady increase in creatinine excretion as infants develop, especially up to the age of 6 months. 41 The effect of creatinine excretion on urinary MMA concentration may be similar in dogs, but this factor has not been assessed.…”

Section: Discussionmentioning

confidence: 99%

Prospective long‐term evaluation of parenteral hydroxocobalamin supplementation in juvenile beagles with selective intestinal cobalamin malabsorption (Imerslund‐Gräsbeck syndrome)

Kook

Reusch

Hersberger

2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundProspective studies on maintenance treatment for Beagles with hereditary selective cobalamin (Cbl) malabsorption (Imerslund‐Gräsbeck syndrome, IGS) are lacking. In our experience, measurement of methylmalonic acid (MMA), a Cbl‐dependent metabolite, seems more helpful to monitor Cbl status as compared with serum Cbl concentrations.ObjectivesTo evaluate a standardized Cbl supplementation scheme in Beagles with IGS. We hypothesized that a single parenteral dose of 1 mg hydroxocobalamin (OH‐Cbl) would maintain clinical and metabolic remission for up to 2 months.AnimalsSix client‐owned juvenile Beagles with genetically confirmed IGS and 28 healthy control dogs.MethodsProspective study. Monthly IM OH‐Cbl (1 mg) supplementation was done over a median of 9 months (range, 6‐13) in 6 dogs, followed by bimonthly (every 2 months) injections in 5 dogs over a median of 6 months (range, 3‐10). Health status was assessed by routine clinical examinations at injection time points and owner observations. Voided urine samples were collected immediately before OH‐Cbl injections for measurement of MMA‐to‐creatinine concentrations using a gas‐liquid chromatography‐tandem mass spectrometry (GC‐MS) method.ResultsAll dogs were clinically healthy while receiving monthly and bimonthly OH‐Cbl supplementation. Urinary MMA results in healthy dogs ranged from 1.3 to 76.5 mmol/mol creatinine (median, 2.9). Median urinary MMA concentrations did not differ between dogs with IGS receiving monthly (n = 49; 5.3 mmol/mol creatinine; range, 2.3‐50.4) and bimonthly (n = 31; 5.3 mmol/mol creatinine; range, 1.6‐50) injections.Conclusions and Clinical ImportanceA maintenance parenteral dose of 1 mg OH‐Cbl monthly or bimonthly appears adequate in Beagles with IGS monitored by metabolic testing.

show abstract

Age-related reference values for urinary organic acids in a healthy Turkish pediatric population

Cited by 71 publications

References 0 publications

The Urinary Metabolome of Healthy Newborns

The Urinary Metabolome of Healthy Newborns

Development and validation of a gas chromatography/mass spectrometry metabonomic platform for the global profiling of urinary metabolites

Prospective long‐term evaluation of parenteral hydroxocobalamin supplementation in juvenile beagles with selective intestinal cobalamin malabsorption (Imerslund‐Gräsbeck syndrome)

Contact Info

Product

Resources

About